The number of deaths among the patients was 227 (10.8%), which included 113 (5.4%) cases of cardiovascular disease (CVD). In multivariate analysis after adjustment for age, albumin, C-reactive protein, comorbidities, etc., the High group was independently and significantly related to all-cause and CVD-related mortality (OR = 2.33, 95% CI: 1.33-4.07, p = 0.002, and OR = 2.09, 95% CI: 1.05-4.14, p = 0.035, respectively). Conclusion: Factoring out fluctuating ERI increases the ability of consistently high ERI levels as an independent risk factor for all-cause and CVD mortality in HD patients.
cluding single-pool Kt/V [4] , phosphorus, calcium [5] , albumin [6] , anemia [7] , blood access catheter use [8, 9] , and a variety of comorbid conditions [10] .
Earlier studies have demonstrated that the need for epoetin (EPO), after adjustments have been made for variables such as hematocrit, stands as an independent predictor of all-cause mortality in HD patients [11] . Based on a prospective trial, López-Gómez et al. [12] reported the relationship between erythropoiesis-stimulating agent (ESA) resistance and 1-year mortality in a group of patients on HD. Furthermore, ESA resistance remained a significant predictor of mortality after adjustment for inflammatory factors such as C-reactive protein (CRP) and IL-6 [13] . It thus appears that resistance to ESA therapy could be clinically useful as an index of comorbidity and as a prognostic marker.
However, previous studies have ignored time-dependent changes of ESA resistance index (ERI), although consistently high ESA resistance was expected to be an adverse phenomenon affecting mortality. The aim of our study was to investigate the presence of variability in the time course of ERI and the association between constantly high ERI level and mortality in HD patients from the Japan Dialysis Outcomes and Practice Patterns Study III (DOPPS III).
Methods
A total of 2,293 HD patients were registered in the Japan DOPPS III (2005) (2006) (2007) (2008) . Out of these, 2,104 patients who had a vintage of 90 days or more and had sufficient data to calculate ERI were analyzed for this research. At each participating dialysis unit, baseline data at the time of patient entry into the study were collected on demographics, medical history, laboratory values, vascular access, anemia measures, medications, and various comorbidities. Data were collected at 4-month intervals on events, including all-cause deaths, and on cardiovascular mortality. Cardiovascular mortality was defined as death attributed to acute myocardial infarction, atherosclerotic heart disease, cardiomyopathy, cardiac arrhythmia, cardiac arrest, pulmonary edema due to exogenous fluid, congestive heart failure, cerebrovascular accident including intracranial hemorrhage, ischemic brain damage or anoxic encephalopathy, pericarditis including cardiac tamponade, valvular heart disease, and pulmonary embolus [14, 15] .
During the DOPPS III investigation, darbepoetin-α was newly approved for use under Japan's healthcare system. The conversion ratio adopted in this study was 200 EPO (EPO-α and -β): 1 darbepoetin-α [16, 17] . ERI was defined as the weekly weight-adjusted dose of EPO divided by hemoglobin (Hb) concentration used to evaluate the dose-response effect in EPO treatment as follows [12, 13] :
ERI (U/kg/week/g per 100 ml) = weekly EPO dose / (weight × Hb).
Ascending quartiles of ERI were determined based on the ERI levels at enrollment. ERI quartile groups were as follows: 1st, <4.08; 2nd, 4.08 to <7.40; 3rd, 7.40 to <11.36; 4th, ≥ 11.36 U/kg/week/g per 100 ml. ERI levels were categorized as low (1st quartile of ERI), intermediate (2nd and 3rd quartiles of ERI), and high (4th quartile of ERI). The average ERI was calculated from ERI levels every 4 months throughout the observation period for each patient. To assess the size of the fluctuation in ERI level during the observation periods according to ERI quartiles at the enrollment periods, we defined six groups of patients on the basis of their overall pattern of fluctuation with reference to a previous report on fluctuation of Hb and mortality [18] 
Statistics
All data were presented as means ± SD unless otherwise specified. Differences between groups were examined with Student's t test or one-way ANOVA for continuous variables, and with χ 2 test for categorical variables. We first evaluated the association of six ERI variation groups on the cumulative incidences of the all-cause and cardiovascular disease (CVD)-related mortality during follow-ups by the Kaplan-Meier method. Next, we estimated the odds ratio (OR) of all-cause and CVD-related mortality by ERI variability groups using logistic regression. To examine patient characteristics associated with all-cause and CVD-related mortality, logistic regression was used. The candidates for explanatory variables included age, sex, vintage, mean albumin ( ≥ 3.5 vs. < 3.5 g/dl), mean CRP ( ≥ 1.0 vs. <1.0 mg/dl), mean normalized protein catabolic rate ( ≥ 1.0 vs. <1.0 g/kg/ day), total cholesterol ( ≥ 200 vs. <200 mg/dl), ferritin ( ≥ 100 vs. <100 ng/ml), phosphorus ( ≥ 6 vs. <6 mg/dl), intact PTH ( ≥ 600 vs. <600 pg/ml), and 14 comorbid conditions (yes vs. no or missing). All significant univariate variables (p < 0.20) and clinically established factors were entered into an intermediate multivariate logistic model of mortality. Then, all the significant multivariate variables detected in the intermediate model and the established factors were entered into a final multivariate logistic mortality model. Statistical significance was defined as p < 0.05. All analyses were performed using SAS version 9.1 (SAS Institute, Cary, N.C., USA) [19] .
Results
A total of 2,104 Japanese HD patients were analyzed. The mean follow-up period of these patients was 109.8 ± 45.0 weeks. Patient characteristics at baseline are summarized in table 1 . In the follow-up period, mean ESA dose calculated as EPO dose was 4,088 ± 2,647 units/week in all patients, 3,936 ± 2,850 units/week in males, and 4,332 ± 2,264 units/week in females. ESA dose was negatively correlated with Hb in both males and females (r = -0.459, p < 0.001; r = -0.356, p < 0.001, respectively). Additionally, ERI distribution pattern did not appear to differ between the sexes, but the average ERI was significantly higher in females than in males (9.96 ± 6.05 vs. 7.18 ± 6.08 U/kg/week/g per 100 ml, p < 0.001).
The patients were divided into six ERI-variability groups based on the ERI quartile levels as follows: the High group, n = 146 (6.9%); the Intermediate group, n = 184 (8.7%); the Low group, n = 247 (11.7%); the intermediatehigh group, n = 483 (23.0%); the low-intermediate group, n = 506 (24.0%); and the low-high group, n = 538 (25.6%). Characteristics of the 6 groups for ERI-variability are shown in table 2 .
Among the 2,104 patients, there were 227 lethal events (10.8%). These events included 113 (5.4%) cases of CVD, 48 cases (2.3%) of infection, 23 cases (1.1%) of cancer, and 5 cases (0.2%) of gastrointestinal bleeding. Of the 113 lethal events due to CVD, 42 were cardiac arrest, 35 were a cerebrovascular accident including intracranial hemorrhage, and 13 were acute myocardial infarction; there were 8 cases of atherosclerotic heart disease, 5 of cardiac arrhythmia, 4 of valvular heart disease, 2 of cardiomyopathy, 2 of pulmonary edema due to exogenous fluid, and 2 of ischemic brain damage and/or anoxic encephalopathy. We first examined all-cause and CVD-related mortality curves in the six ERI variability groups by the Kaplan-Meier method ( fig. 2 ) , in which all-cause and CVD-related mortality rates were highest in the High ERI group. Figure 3 shows unadjusted ORs for all-cause and CVDrelated mortality in each ERI variability group. The risk for all-cause mortality in the High group was significantly higher than in the other groups, as shown in figure 3 a (OR = 4.28, 95% CI: 2.47-7.39, p = 0.001). The High group was also significantly associated with CVD-related mortality (OR = 2.86, 95% CI: 1.38-5.94, p = 0.004; fig. 3 b) .
In a multivariate logistic regression model adjusted for age, sex, ferritin, PCR, albumin, CRP, phosphorus, and 14 comorbidities, the High group had significantly higher risk for all-cause mortality (OR = 2.33, 95% CI: 1.33-4.07, p = 0.002; table 3 ). For CVD-related mortality, the High group had significantly higher risk adjusted for the above variables except for phosphorus (OR = 2.09, 95% CI: 1.05-4.14, p = 0.035).
Next, we examined factors related to the High group. The High group was associated with older age and had a shorter HD vintage, lower body weight, BMI, hemoglobin, creatinine, blood urea nitrogen and albumin, and a higher prevalence of several comorbidities such as cerebrovascular disease and gastrointestinal bleeding compared to other groups ( table 4 ) .
Discussion
This study demonstrated the positive association of ERI variability with mortality in HD patients in Japan. Amplitude fluctuations in ERI levels are very common, with 72.6% of patients having ERI levels in some degree of flux during the observational period. However, the High group, which had consistently high ERI levels, was a high risk population for all-cause and CVD-related mortality in HD patients compared with three amplitude fluctuation groups. Thus, maintaining consistently high ERI levels was a strong independent risk factor for all-cause and CVD-related mortality. Our findings demonstrate that evaluation of ERI variability is one of the important prognostic markers. This study contributed to the elucidation of the cumulative effect of high ERI levels on prognosis. Patients in the High group are likely to have adverse conditions continuously throughout the observational period. Adverse conditions worsen prognosis in proportion to the period during which they are present. As this study has demonstrated, cumulative estimation of comprehensive index for adverse conditions such as ERI variability is needed as an applicative marker to predict poor prognosis adequately.
The High group was found to be associated with older age, low BMI, short HD vintage, low hemoglobin, low creatinine, low blood urea nitrogen, low albumin, and several comorbidities. These findings seem consistent with the ex- isting knowledge of ERI-related factors derived from previous reports [11-13, 20, 21] . Recently, it was reported that ERI was lower in HD patients with higher levels of albumin [22] . In addition to comorbidity factors such as heart failure or CVD previously reported [23] , cancer, diabetes mellitus, gastrointestinal bleeding, and neurologic disorders were related to the High group. These findings suggest that comorbidity factors related to ERI variability might differ from those related to simple ERI levels. CRP was found not to be associated with the High group, although inflammatory conditions can elevate ERI by inducing cytokines that suppress erythropoiesis [24, 25] . This was probably because the Low group, which had consistently low ERI levels, showed an unexpectedly high CRP. Examination of high CRP in the Low and High groups will provide a clue as to how factors affecting inflammation elevate ERI. In our study, ERI levels seemed lower than those in a previous report [12] . This is partially because ESA dosing is lower in Japan than elsewhere [2] , and this low ERI may predict a favorable outcome in Japanese HD patients [7] . If higher ESA dosing were available in the Japanese healthcare system, patients with adverse conditions causing high resistance to ESA might have higher ERI. ERI of a less limited range may be expected to yield greater precision in prognostic predictions. To determine the impact of dosing range, further study of ERI's availability worldwide should be undertaken. For a clinical and pathological understanding of ERI, it would be beneficial to investigate how low ERI is affected by a limited range of ESA dosing or other factors.
The strengths of the present analysis are the large number of randomly selected HD patients and representative sample of dialysis facilities in Japan. Our current findings may be generalizable to the broad maintenance HD population. The present study has some limitations that are mainly due to the observational nature of the DOPPS. Our analysis of ERI was based on data collected at 4-month intervals. By using different measurement frequencies, it might be possible to elevate the prognostic potential of ERI variability. In subsequent investigations, therefore, the most appropriate measurement frequencies and duration should be clarified. This investigation was an observational study and not designed for intervention. Hence, further study is needed to investigate the causal relationship between the High group and mortality, and provide additional insights into the underlying mechanisms by which ERI predicts lethal events.
Conclusion
This investigation has revealed that factoring out fluctuating ERI increases the ability of consistently high ERI levels as an independent risk factor for all-cause and CVD mortality in HD patients. Further study including timedependent ERI grouping should provide a more detailed understanding of the mechanisms that underlie the causal relationship between ERI and mortality.
